6:09 PM
 | 
Mar 30, 2007
 |  BC Extra  |  Company News

Cephalon gets second Nuvigil approvable letter

CEPH said late Friday that it received a second approvable letter for Nuvigil armodafinil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome and shift work sleep disorder. CEPH said the letter contained draft labeling that included a proposed bolded...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >